Portfolio Equity Curve — % Return from $1M
── Portfolio ── S1 IVR ── S2 VIX TS ── S3 Disp ── Combined
Key Performance Metrics
Total P&L by Signal (in $000s)
Annual Return — 2018 → 2025
Walk-Forward Sharpe — 6-Month OOS Windows
11/13 negative
Per-Signal Performance Breakdown
Signal Sharpe Ann. Return Win Rate N Trades Total P&L Status
Key Finding — Why the Strategy Underperformed
S1 −$502,671 S1 (IVR/PDV) goes short gamma when IVR is high relative to PDV. In 2018, 2019, and 2024 — all elevated-vol years — realised vol stayed elevated, meaning premium sellers systematically underpriced tail risk.
COSTS −$334,537 Total transaction costs (bid-ask + commissions + slippage) consumed $334k over 7 years — offsetting any alpha in the signal.
REGIME MISMATCH 52.9% of backtest days were R2 (VOMMA_ACTIVE) — a regime favouring vomma trades, not gamma strategies. S1 and S2 were trading in the wrong regime for 952 / 1800 days.
Only Profitable Signal — S3 Dispersion
S3 +$21,003 S3 (VIX/VVIX ratio proxy) is long-only — buys when volatility appears cheap relative to vol-of-vol. 14 trades in 7 years with 92.9% win rate.
The strategy's rarity is its strength: it fires only when the signal is extreme, and it tends to correctly identify vol spikes after entry.
BEST DAY 2024-12-20 +3.69% — day after the worst day, as the FOMC panic resolved and vol mean-reverted.
Annual Returns Heatmap
2018
-8.6%
2019
-3.8%
2020
-1.6%
2021
+1.1%
2022
-3.6%
2023
+2.3%
2024
-6.6%
2025
-2.4%